Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
Aim: Patients with polycythemia vera (PV), a rare and chronic blood cancer, are at a higher risk for thromboembolic events, progression to myelofibrosis, and leukemic transformation. In 2021, ropeginterferon alfa-2b-njft (BESREMi R ) was approved in the US to treat adults with PV. The purpose of...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Becaris Publishing Limited
2023-08-01
|
| Cyfres: | Journal of Comparative Effectiveness Research |
| Pynciau: | |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|